ImmPACT Bio is at the forefront of developing innovative chimeric antigen receptor (CAR) T-cell therapies aimed at addressing significant medical challenges in oncology and autoimmune diseases. Their technology encompasses several platforms, including bispecific CAR T cells designed to prevent antigen escape and to target the immunosuppressive tumor microenvironment. One notable platform, the TGF-β CAR, is engineered to rewire T cell responses to counteract the suppressive effects of soluble factors in cancer, thereby enhancing the efficacy of the immune response against tumors. Additionally, ImmPACT Bio's iCAR technology allows for the selective targeting and destruction of cancer cells while sparing normal tissues, which holds promise for treating a wide range of solid tumors.

The company is also advancing its IMPT-601 therapy, a bispecific CAR T-cell treatment that targets Claudin18.2 and TGF-β, specifically designed to enhance CAR T-cell infiltration and reduce T-cell exhaustion within the tumor microenvironment. This dual-targeting approach aims to improve the persistence and effectiveness of CAR T cells in combating gastric cancer. ImmPACT Bio's research is grounded in the pioneering work of scientists from UCLA, and their technologies are positioned to transform the landscape of cell therapies by addressing critical limitations of current treatments, such as antigen escape and immune suppression.

On October 31, 2024, Lyell Immunopharma, Inc. acquired ImmPACT Bio

United States

ImmPACT Bio is dedicated to the discovery of transformative CAR-T cell therapies for cancer patients who have exhausted their treatment options. Our technology is designed to precisely distinguish cancerous cells from normal cells; thereby eliminating tumors without damaging normal tissues. Our goal is to eradicate tumors without generating the severe side effects that are difficult, sometimes impossible, for cancer patients to endure.

ImmPACT Bio

Company Details